{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:27:12Z","timestamp":1772166432551,"version":"3.50.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T00:00:00Z","timestamp":1694736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T00:00:00Z","timestamp":1694736000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"crossref","award":["DFG- SCHL 2118\/2-1"],"award-info":[{"award-number":["DFG- SCHL 2118\/2-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018936","name":"Universit\u00e4tsklinikum Heidelberg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100018936","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      About 50% of older patients with acute myeloid leukemia (AML) fail to attain complete remission (CR) following cytarabine plus anthracycline-based induction therapy. Salvage chemotherapy regimens are based on high-dose cytarabine (HiDAC), which is frequently combined with mitoxantrone (HAM regimen). However, CR rates remain low, with less than one-third of the patients achieving a CR.\n                      <jats:italic>FLT3<\/jats:italic>\n                      -ITD has consistently been identified as an unfavorable molecular marker in both relapsed and refractory (r\/r)-AML. One-quarter of patients who received midostaurin are refractory to induction therapy and relapse rate at 2 years exceeds 40%. The oral second-generation bis-aryl urea tyrosine kinase inhibitor quizartinib is a very selective\n                      <jats:italic>FLT3<\/jats:italic>\n                      inhibitor, has a high capacity for sustained\n                      <jats:italic>FLT3<\/jats:italic>\n                      inhibition, and has an acceptable toxicity profile.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In this multicenter, upfront randomized phase II trial, all patients receive quizartinib combined with HAM (cytarabine 3g\/m\n                      <jats:sup>2<\/jats:sup>\n                      bidaily day one to day three, mitoxantrone 10mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      days two and three) during salvage therapy. Efficacy is assessed by comparison to historical controls based on the matched threshold crossing approach with achievement of CR, complete remission with incomplete hematologic recovery (CRi), or complete remission with partial recovery of peripheral blood counts (CRh) as primary endpoint. During consolidation therapy (chemotherapy and allogeneic hematopoietic cell transplantation), patients receive either prophylactic quizartinib therapy or measurable residual disease (MRD)-triggered preemptive continuation therapy with quizartinib according to up-front randomization.\n                    <\/jats:p>\n                    <jats:p>The matched threshold crossing approach is a novel study-design to enhance the classic single-arm trial design by including matched historical controls from previous clinical studies. It overcomes common disadvantages of single-armed and small randomized studies, since the expected outcome of the observed study population can be adjusted based on the matched controls with a comparable distribution of known prognostic and predictive factors. Furthermore, balanced treatment groups lead to stable statistical models. However, one of the limitations of our study is the inability to adjust for unobserved or unknown confounders.<\/jats:p>\n                    <jats:p>\n                      Addressing the primary endpoint, CR\/CRi\/CRh after salvage therapy, the maximal sample size of 80 patients is assessed generating a desirable power of the used adaptive design, assuming a logistic regression is performed at a one-sided significance level\n                      <jats:italic>\u03b1<\/jats:italic>\n                      =0.05, the aspired power is 0.8, and the number of matching partners per intervention patient is at least 1. After enrolling 20 patients, the trial sample size will be recalculated in an interim analysis based on a conditional power argument.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Currently, there is no commonly accepted standard for salvage chemotherapy treatment. The objective of the salvage therapy is to reduce leukemic burden, achieve the best possible remission, and perform a hemopoietic stem-cell transplantation. Thus, in patients with\n                      <jats:italic>FLT3<\/jats:italic>\n                      -ITD mutation, the comparison of quizartinib with intensive salvage therapy versus chemotherapy alone appears as a logical consequence in terms of efficacy and safety.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>Ethical approval and approvals from the local and federal competent authorities were granted. Trial results will be reported via peer-reviewed journals and presented at conferences and scientific meetings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>ClinicalTrials.gov NCT03989713; EudraCT Number: 2018-002675-17.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13063-023-07421-x","type":"journal-article","created":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T08:01:54Z","timestamp":1694764914000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Q-HAM: a multicenter upfront randomized phase II trial of quizartinib and high-dose Ara-C plus mitoxantrone in relapsed\/refractory AML with FLT3-ITD"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2397-3070","authenticated-orcid":false,"given":"Sonia","family":"Jaramillo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucian","family":"Le Cornet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Kratzmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Krisam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"G\u00f6rner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathias","family":"H\u00e4nel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"R\u00f6llig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maxi","family":"Wass","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Scholl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Ringhoffer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Reichart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bj\u00f6rn","family":"Steffen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabine","family":"Kayser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan-Henrik","family":"Mikesch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerstin","family":"Schaefer-Eckart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f6rg","family":"Schubert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Geer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonja","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meinhard","family":"Kieser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim","family":"Sauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharina","family":"Kriegsmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Hundemer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hubert","family":"Serve","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Bornh\u00e4user","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carsten","family":"M\u00fcller-Tidow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard F.","family":"Schlenk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,9,15]]},"reference":[{"issue":"11","key":"7421_CR1","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1002\/ajh.25975","volume":"95","author":"EH Estey","year":"2020","unstructured":"Estey EH. Acute myeloid leukemia: 2021 update on risk-stratification and management. Am J Hematol. 2020;95(11):1368\u201398. https:\/\/doi.org\/10.1002\/ajh.25975.","journal-title":"Am J Hematol."},{"issue":"1","key":"7421_CR2","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1182\/blood-2015-08-604520","volume":"127","author":"H Dombret","year":"2016","unstructured":"Dombret H, Gardin C. An update of current treatments for adult acute myeloid leukemia. Blood. 2016;127(1):53\u201361.","journal-title":"Blood"},{"issue":"12","key":"7421_CR3","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1007\/s00277-017-3150-3","volume":"96","author":"G Nagel","year":"2017","unstructured":"Nagel G, Weber D, Fromm E, et al. Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO). Ann Hematol. 2017;96(12):1993\u20132003.","journal-title":"Ann. Hematol."},{"issue":"3","key":"7421_CR4","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1182\/blood.V98.3.548","volume":"98","author":"RM Stone","year":"2001","unstructured":"Stone RM, Berg DT, George SL, et al. Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine. Blood. 2001;98(3):548\u201353.","journal-title":"Blood"},{"issue":"20","key":"7421_CR5","doi-asserted-by":"publisher","first-page":"2758","DOI":"10.1200\/JCO.2010.32.8500","volume":"29","author":"C R\u00f6llig","year":"2011","unstructured":"R\u00f6llig C, Bornh\u00e4user M, Thiede C, et al. Long-term prognosis of acute myeloid leukemia according to the new genetic risk classification of the European LeukemiaNet recommendations: evaluation of the proposed reporting system. J Clin Oncol. 2011;29(20):2758\u201365.","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"7421_CR6","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1038\/leu.2017.23","volume":"31","author":"M Wattad","year":"2017","unstructured":"Wattad M, Weber D, D\u00f6hner K, et al. Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failure. Leukemia. 2017;31(6):1306\u201313.","journal-title":"Leukemia"},{"issue":"5","key":"7421_CR7","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1038\/leu.2017.22","volume":"31","author":"RF Schlenk","year":"2017","unstructured":"Schlenk RF, Frech P, Weber D, et al. Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia. Leukemia. 2017;31(5):1217\u201320.","journal-title":"Leukemia"},{"issue":"26","key":"7421_CR8","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1182\/blood.2020005998","volume":"136","author":"S Kapp-Schwoerer","year":"2020","unstructured":"Kapp-Schwoerer S, Weber D, Corbacioglu A, et al. Impact of gemtuzumab ozogamicin on MRD and relapse risk in NPM1 mutated AML patients: results from the AMLSG 09\u201309 Trial. Blood. 2020;136(26):3041\u201350. https:\/\/doi.org\/10.1182\/blood.2020005998.","journal-title":"Blood"},{"key":"7421_CR9","doi-asserted-by":"publisher","first-page":"865","DOI":"10.3324\/haematol.2016.159343","volume":"102","author":"SA Buckley","year":"2017","unstructured":"Buckley SA, et al. Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: A meta-analysis. Haematologica. 2017;102:865\u201373.","journal-title":"Haematologica."},{"issue":"6","key":"7421_CR10","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1097\/CCO.0000000000000404","volume":"29","author":"R Schlenk","year":"2017","unstructured":"Schlenk R, M\u00fcller-Tidow C, Benner A, et al. Relapsed\/refractory Acute Myeloid Leukemia \u2013 Any Progress? Curr Opin Oncol. 2017;29(6):467\u201373.","journal-title":"Curr Opin Oncol."},{"issue":"5","key":"7421_CR11","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1056\/NEJMoa1614359","volume":"377","author":"RM Stone","year":"2017","unstructured":"Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 Mutation. N Engl J Med. 2017;377(5):454\u201364.","journal-title":"N. Engl. J. Med."},{"issue":"23","key":"7421_CR12","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1182\/blood.V126.23.322.322","volume":"126","author":"R Schlenk","year":"2015","unstructured":"Schlenk R, D\u00f6hner K, Salih H, et al. Midostaurin in combination with intensive induction and as single agent maintenance therapy after consolidation therapy with allogeneic hematopoietic stem cell transplantation or high-dose cytarabine (NCT01477606). Blood. 2015;126(23):322.","journal-title":"Blood"},{"issue":"29","key":"7421_CR13","doi-asserted-by":"publisher","first-page":"3681","DOI":"10.1200\/JCO.2013.48.8783","volume":"31","author":"JE Cortes","year":"2013","unstructured":"Cortes JE, Kantarjian H, Foran JM, et al. Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3\u2013internal tandem duplication status. J Clin Oncol. 2013;31(29):3681\u20137.","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"7421_CR14","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/S1470-2045(18)30240-7","volume":"19","author":"J Cortes","year":"2018","unstructured":"Cortes J, Perl AE, D\u00f6hner H, et al. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2018;19(7):889\u2013903.","journal-title":"Lancet. Oncol."},{"issue":"6","key":"7421_CR15","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1182\/blood-2018-01-821629","volume":"132","author":"JE Cortes","year":"2018","unstructured":"Cortes JE, Tallman MS, Schiller GJ, et al. Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD-mutated, relapsed or refractory AML. Blood. 2018;132(6):598\u2013607.","journal-title":"Blood"},{"key":"7421_CR16","unstructured":"Cortes J, Khaled S, Martinelli G, et al. Quizartinib significantly prolongs overall survival in patients with FLT3-internal tandem duplicationmutated (MUT) relapsed\/refractory AML in the phase 3, randomized, controlled QuANTUM-R trial, in 23th Congress of the European Hematology Association, 2018, LB2600."},{"issue":"21","key":"7421_CR17","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1182\/blood.V122.21.623.623","volume":"122","author":"JK Altman","year":"2013","unstructured":"Altman JK, Foran JM, Pratz KW, et al. Results of a phase 1 study of quizartinib (AC220, ASP2689) in combination with induction and consolidation chemotherapy in younger patients with newly diagnosed acute myeloid leukemia. Blood. 2013;122(21):623.","journal-title":"Blood"},{"issue":"21","key":"7421_CR18","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1182\/blood.V122.21.622.622","volume":"122","author":"A Burnett","year":"2013","unstructured":"Burnett A, Bowen D, Russell N, et al. AC220 (Quizartinib) can be safely combined with conventional chemotherapy in older patients with newly diagnosed acute myeloid leukaemia: experience from the AML18 pilot trial. Blood. 2013;122(21):622.","journal-title":"Blood"},{"issue":"Suppl5","key":"7421_CR19","first-page":"v355","volume":"28","author":"R Schlenk","year":"2017","unstructured":"Schlenk R, Dombret H, Amadori S, et al. QuANTUM-First: phase 3, double-blind, placebo-controlled study of quizartinib in combination with induction and consolidation chemotherapy, and as maintenance therapy in patients with newly diagnosed FLT3-ITD acute myeloid leukemia. Ann Oncol. 2017;28(Suppl5):v355\u201371.","journal-title":"Ann. Oncol."},{"key":"7421_CR20","unstructured":"DAIICHI SANKYO. Quizartinib (AC220) Investigator\u2019s Brochure, Version 14. San Diego, 2020."},{"issue":"15_suppl","key":"7421_CR21","doi-asserted-by":"publisher","first-page":"7021","DOI":"10.1200\/jco.2013.31.15_suppl.7021","volume":"31","author":"G Martinelli","year":"2013","unstructured":"Martinelli G, Perl AE, Dombret H, et al. Effect of quizartinib (AC220) on response rates and long-term survival in elderly patients with FLT3-ITD positive or negative relapsed\/refractory acute myeloid leukemia. J Clin Oncol. 2013;31(15_suppl):7021.","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"7421_CR22","doi-asserted-by":"publisher","first-page":"7012","DOI":"10.1200\/jco.2013.31.15_suppl.7012","volume":"31","author":"JE Cortes","year":"2013","unstructured":"Cortes JE, Perl AE, Dombret H, et al. Response rate and bridging to hematopoietic stem cell transplantation (HSCT) with quizartinib (AC220) in patients with FLT3-ITD positive or negative relapsed\/refractory AML after second-line chemotherapy or previous bone marrow transplant. J Clin Oncol. 2013;31(15_suppl):7012.","journal-title":"J Clin Oncol"},{"key":"7421_CR23","doi-asserted-by":"crossref","unstructured":"Levis MJ, Cortes JE, Perl A. High Response Rate and Bridging to Hematopoietic Stem Cell Transplantation with Quizartinib (AC220) in Patients with FLT3-ITD-Positive Relapsed\/Refractory Acute Myeloid Leukemia (AML)., in he 18th Congress of the European Hematology Association, 2013, P043.","DOI":"10.1200\/jco.2013.31.15_suppl.7012"},{"key":"7421_CR24","doi-asserted-by":"crossref","unstructured":"Schiller G, Tallman M, Goldberg S, et al. Final results of a randomized phase 2 study showing the clinical benefit of quizartinib (AC220) in patients with FLT3-ITD positive relapsed or refractory acute myeloid leukemia, in American Society of Clinical Oncology Annual Meeting, 2014, Abstract 385.","DOI":"10.1200\/jco.2014.32.15_suppl.7100"},{"key":"7421_CR25","unstructured":"Krisam J, Weber D, Schlenk RF, et al. Matched-Threshold-Crossing (MTC): a novel trial design to enhance single-arm phase II trials by including matched control patients, in 63. Jahrestagung der Deutschen Gesellschaft f\u00fcr Medizinische Informatik, Biometrie und Epidemiologie e.V. (GMDS)., 2018."},{"issue":"3","key":"7421_CR26","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1182\/blood-2009-11-254441","volume":"116","author":"D Grimwade","year":"2010","unstructured":"Grimwade D, Hills RK, Moorman AV, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116(3):354\u201365.","journal-title":"Blood"},{"key":"7421_CR27","unstructured":"Fayers P, Aaronson NK, Bjordal K, et al. EORTC QLQ-C30 scoring manual. European Organisation for Research and Treatment of Cancer, 2001."},{"key":"7421_CR28","unstructured":"Buysse DJ, Reynolds CF, Monk TH, et al. Pittsburgh sleep quality index., in APA task force. Handbook of psychiatric measures, Rush A. J. et al., Ed. Washington DC: APA; 2000. p. 678\u201380."},{"key":"7421_CR29","unstructured":"Patient Health Questionnaire (PHQ) Screeners. INSTRUCTION MANUAL Instructions for Patient Health Questionnaire (PHQ) and GAD-7 Measures."},{"key":"7421_CR30","unstructured":"International committee of medical journal editors. Recommendations for the conduct, reporting, editing, and publication of scholarly work in medical journals. https:\/\/www.icmje.org\/recommendations\/. Accessed 16 Jan 2023."},{"key":"7421_CR31","doi-asserted-by":"crossref","unstructured":"Edelmann D, Habermehl C, Schlenk RF, Benner A. Adjusting Simon's optimal two\u2010stage design for heterogeneous populations based on stratification or using historical controls. Biometrical J. 201962:311\u201329.","DOI":"10.1002\/bimj.201800390"},{"issue":"15","key":"7421_CR32","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1200\/JCO.2009.26.3343","volume":"28","author":"HK Gan","year":"2010","unstructured":"Gan HK, Grothey A, Pond GR, et al. Randomized phase II trials: inevitable or inadvisable? J Clin Oncol. 2010;28(15):2641\u20137.","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"7421_CR33","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1214\/aos\/1176350951","volume":"16","author":"RJ Gray","year":"1988","unstructured":"Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16(3):1141\u201354.","journal-title":"Ann. Stat."},{"issue":"12","key":"7421_CR34","doi-asserted-by":"publisher","first-page":"3294","DOI":"10.1182\/blood-2010-08-301796","volume":"117","author":"M Levis","year":"2011","unstructured":"Levis M, Ravandi F, Eunice S, et al. Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood. 2011;117(12):3294\u2013301.","journal-title":"Blood"},{"issue":"346","key":"7421_CR35","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e7586","volume":"8","author":"AW Chan","year":"2013","unstructured":"Chan AW, Tetzlaff JM, G\u00f8tzsche PC, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;8(346): e7586.","journal-title":"BMJ."},{"key":"7421_CR36","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1182\/blood.V128.22.1069.1069","volume":"128","author":"AE Perl","year":"2016","unstructured":"Perl AE, Altman JK, Cortes JE, et al. Final results of the chrysalis trial: a first-in-human phase 1\/2 dose-escalation, dose-expansion study of gilteritinib (ASP2215) in patients with relapsed\/refractory acute myeloid leukemia (R\/R AML). Blood. 2016;128:1069.","journal-title":"Blood"},{"issue":"18","key":"7421_CR37","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","volume":"381","author":"AE Perl","year":"2019","unstructured":"Perl AE, Martinelli G, Cortes JE, et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N Engl J Med. 2019;381(18):1728\u201340.","journal-title":"N Engl J Med."},{"issue":"7","key":"7421_CR38","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/S1470-2045(19)30150-0","volume":"20","author":"JE Cortes","year":"2019","unstructured":"Cortes JE, Khaled S, Martinelli G, Perl AE, et al. Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2019;20(7):984\u201397.","journal-title":"Lancet Oncol"},{"key":"7421_CR39","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1007\/s00277-018-3304-y","volume":"97","author":"JE Meg\u00edas-Vericat","year":"2018","unstructured":"Meg\u00edas-Vericat JE, Mart\u00ednez-Cuadr\u00f3n D, Sanz MA, Montesinos P. Salvage regimens using conventional chemotherapy agents for relapsed\/refractory adult AML patients: a systematic literature review. Ann Hematol. 2018;97:1115\u201353.","journal-title":"Ann Hematol"},{"issue":"9","key":"7421_CR40","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.3324\/haematol.2018.203869","volume":"104","author":"R Ram","year":"2019","unstructured":"Ram R, Scheid C, Amit O, et al. Sequential therapy for patients with primary refractory acute myeloid leukemia: a historical prospective analysis of the German and Israeli experience. Haematologica. 2019;104(9):1798\u2013803.","journal-title":"Haematologica."},{"issue":"9","key":"7421_CR41","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/S1470-2045(15)00201-6","volume":"16","author":"F Ravandi","year":"2015","unstructured":"Ravandi F, Ritchie EK, Sayar H, et al. Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study. Lancet Oncol. 2015;16(9):1025\u201336.","journal-title":"Lancet Oncol."},{"issue":"18","key":"7421_CR42","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1200\/JCO.2013.52.8562","volume":"32","author":"GJ Roboz","year":"2014","unstructured":"Roboz GJ, Rosenblat T, Arellano M, et al. International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed\/refractory acute myeloid leukemia. J Clin Oncol. 2014;32(18):1919\u201326.","journal-title":"J Clin Oncol."},{"issue":"9","key":"7421_CR43","doi-asserted-by":"publisher","first-page":"e398","DOI":"10.3324\/haematol.2018.211615","volume":"104","author":"A Bazarbachi","year":"2019","unstructured":"Bazarbachi A, Labopin M, Battipaglia G, Djabali A, et al. Sorafenib improves survival of FLT3-mutated acute myeloid leukemia in relapse after allogeneic stem cell transplantation: a report of the EBMT Acute Leukemia Working Party. Haematologica. 2019;104(9):e398\u2013401.","journal-title":"Haematologica"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-023-07421-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-023-07421-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-023-07421-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T11:32:56Z","timestamp":1700220776000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-023-07421-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,15]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["7421"],"URL":"https:\/\/doi.org\/10.1186\/s13063-023-07421-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1117424\/v1","asserted-by":"object"}]},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,15]]},"assertion":[{"value":"26 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Before the start of the trial, the trial protocol, informed consent document, and any other appropriate documents are submitted to the independent Ethics Committee (EC) as well as to the competent federal authority (BfArM). A written favorable vote of the EC and an (implicit) approval by the competent higher federal authority are a prerequisite for initiation of the clinical trial. The statement of EC should contain the title of the trial, the trial code, the trial site, and a list of reviewed documents. It must mention the date on which the decision was made and must be officially signed by a committee member. Before the first patient is enrolled in the trial, all ethical and legal requirements must be met. All planned substantial changes (see \u00a710, (1) of German GCP-Regulation) are to be submitted to EC and the competent federal authority in writing as amendments. They have to be approved by the EC and the competent federal authority. The Coordinating Investigator or the NCT Trial Center, and if applicable the investigator(s) are keeping a record of all communication with the EC and the regulatory authorities. Pursuant to the German Drug Law (AMG) and the GCP Regulation, the EC and the competent higher federal authority are informed of all suspected unexpected serious unexpected adverse reactions (SUSARs) and all AEs resulting in death or being life-threatening, which occur during the trial. Both institutions are informed in case the benefit-risk assessment did change or any other new and significant hazards for patients\u2019 safety or welfare did occur. Furthermore, a report on all observed serious adverse events (SAEs) is submitted once a year (Development Safety Update Report (DSUR)). The EC and the regulatory authorities must be informed of the end of the trial. They have to be provided with a summary of trial results within one year after the end of the clinical phase (LPLV).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The first author signs for and accepts responsibility for releasing this material on behalf of any and all co-authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"591"}}